Clinical trials: Cardiac Ischemia
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter
The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world.
- Trial name
- NCT06385067
- Testing
- Biolimus Coated Coronary Artery Balloon Dilation Catheter
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- JW Medical Systems Ltd
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Stable Angina
Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention
Pressure intermittent coronary sinus occlusion (PICSO) in patients with coronary artery disease improves collateral flow index to higher than 30%. PICSO used in this patient population is safe, feasible and effective.
- Trial name
- PICSO (NCT01308125)
- Testing
- PICSO
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Miracor Medical SA
Acute Myocardial Infarction (AMI), Coronary Occlusion
AngelMed for Early Recognition and Treatment of STEMI
A prospective, randomized multicenter study of subjects with a high-risk of having a myocardial infarction (MI) due to acute coronary syndrome or bypass surgery.
- Conditions
- Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
- Trial name
- ALERTS (NCT00781118)
- Testing
- Guardian System
- Where
- 95 sites in United States
- Volunteers
- 1,020 people
- Sponsor
- Angel Medical Systems
Coronary Artery Disease
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry
The e-Ultimaster will further validate the safety and efficacy of Ultimaster DES system in unselected patients representing everyday clinical practice.
- Trial name
- e-Ultimaster (NCT02188355)
- Where
- 462 sites in Argentina, Armenia and 48 more
- Volunteers
- 37,000 people
- Sponsor
- Terumo Europe N.V.
Acute Coronary Syndrome
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED).
- Trial name
- NCT00077818
- Testing
- Enoxaparin sodium
- Sponsor
- Sanofi
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
- Trial name
- VITALYST EFS (NCT06132568)
- Testing
- VITALYST System
- Where
- 5 sites in United States, Sweden
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Cardiovascular Diseases, Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS)…
- Conditions
- Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease
- Trial name
- NCT05566678
- Testing
- Cigarette, THS, Smoking Abstinence
- Sponsor
- Philip Morris Products S.A.
Angina Pectoris
A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
The multi-centric, open label, single arm and self controlled study is planned to assess the efficacy of orally administered Sigmart in subjects with recurrent angina after coronary revascularization.
- Trial name
- SIGMART (NCT01185015)
- Testing
- Sigmart (nicorandil)
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus Type 2
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no…
- Trial name
- NCT01680978
- Testing
- aleglitazar
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio.
- Conditions
- Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina
- Trial name
- LESS (NCT04897126)
- Testing
- Shexiang Baoxin pill（MUSKARDIA）
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Heart Failure
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting…
- Trial name
- HEAL-AHF (NCT06340048)
- Testing
- HiCM-188 therapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Chronic Heart Failure
A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
The purpose of this study is to assess the safety, efficacy and optimal dose of TSG-01, an innovative drug with ginsenosides as its main components, in the treatment of patients with chronic heart failure(CHF).
- Trial name
- NCT04515290
- Testing
- TSG-01
- Where
- 5 sites in China
- Volunteers
- 85 people
- Sponsor
- Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG)…
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
- Trial name
- NCT00402506
- Testing
- (MC-1) Pyridoxal 5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- Medicure
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences
Acute Coronary Syndrome (ACS), Myocardial Infarction
VITROS Immunodiagnostic Products hs Troponin I
The purpose of this clinical study is to collect data to substantiate the use of the VITROS hs Troponin I test as an aid in the diagnosis of myocardial infarction (MI).
- Trial name
- NCT03581578
- Where
- 24 sites in United States
- Volunteers
- 1,630 people
- Sponsor
- Ortho-Clinical Diagnostics, Inc.
Coronary Artery Disease
Post-Market Registry of the ACIST CPM System and Navvus Catheter in Clinical Practice
This registry will collect real-world clinical evidence on the performance, safety, and usability of the ACIST CPM System and NAVVUS Catheter when used in accordance with approved labeling in a European commercial setting.
- Trial name
- ADVANCE-EU (NCT02060682)
- Testing
- Navvus Catheter FFR
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Acist Medical Systems
Coronary Artery Disease
The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial
The ASPECT study is an Asian multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Cook Incorporated Paclitaxel Eluting Supra G Coronary Stent to reduce restenosis in the coronary…
- Trial name
- NCT00196079
- Testing
- Coronary stent
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Cook Group Incorporated
Heart Failure Class II or III
C-Cure Clinical Trial
The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells (C-Cure) in the setting of chronic heart failure…
- Trial name
- NCT00810238
- Testing
- C-Cure
- Where
- 8 sites in Belgium, Serbia
- Volunteers
- 240 people
- Sponsor
- Celyad Oncology SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.